Sorrento Therapeutics to Present at the JMP Securities Life Sciences Conference in New York (NY)

NEXT STORY
G1 Therapeutics to Present Patient-Reported Outcomes (PRO) Data on Trilaciclib At Multinational Association of Supportive Care in Cancer (MASCC) And International Society of Oral Oncology (ISCOO) 2019 Annual Meeting
PREV STORY
TLC Announces Part 1 Analysis of TLC590 Phase II Clinical Trial for Postsurgical Pain Management following Bunionectomy
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Aptevo Therapeutics Presents New Patient-Reported Data With IXINITY

Data Presented at the Thrombosis and Hemostasis 2018 Summit of North America SEATTLE, March ...

author_avatar
NASDAQ Market News

Cellceutix Phase 2 Brilacidin Trial Progresses to Highest Dose Cohort for the Induction of Remission of Mild-to-Moderate Ulcerative Colitis

BEVERLY, Mass., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Cellceutix Corporation, (OTCQB:CTIX) (“the Company”), a ...

author_avatar
NASDAQ Market News

Theratechnologies développera la tésamoréline pour le traitement du NASH chez la population générale

author_avatar
NASDAQ Market News